PPIs linked to risk for severe infection, decompensation in patients with cirrhosis

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress.“The safety of PPIs in cirrhosis remains quite controversial,” Nadim Mahmud, MD, MS, MPH, MSCE, assistant professor of medicine and epidemiology at the University of Pennsylvania Perelman School of Medicine, told attendees. “There is conflicting data regarding the impact of PPIs on several key liver-related adverse events, includingRead More

Categories: News

Related Articles

2018 FGS Annual Meeting Registration Is Now Open!

Registration for the 2018 FGS Annual Meeting is now open! We will be returning to the Hyatt Regency Grand Cypress this September 14-16, 2018. Short…

Justin Bouck May 22, 2018

PPI use should be limited to appropriate indications, lowest effective dose in cirrhosis

Although proton pump inhibitors were linked with an increased risk for infection and decompensation in patients with cirrhosis, they may still be of benefit in…

No increased CV, death risk with ticagrelor plus proton pump inhibitor therapy after PCI

Concomitant proton pump inhibitor plus ticagrelor monotherapy after PCI does not increase risk for all-cause death or an adverse CV event, in contrast with conventional…

Support vector machines lead machine learning models in predicting liver decompensation

LONDON — Support vector machines had the highest accuracy in predicting liver decompensation among a subset of patients in Germany compared with other machine learning…

Paternal exposure to most IBD medications not linked to adverse neonatal outcomes

SAN DIEGO — Paternal exposure to the majority of therapies for inflammatory bowel disease did not increase the risk for adverse neonatal outcomes, according to…